Next Article in Journal
A Review of Multidisciplinary Interventions in Atopic Dermatitis
Next Article in Special Issue
Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients
Previous Article in Journal
Pattern of Investigation Reflects Risk Profile in Emergency Medical Admissions
Previous Article in Special Issue
Current Cervical Carcinoma Screening Guidelines
Open AccessReview

Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer

Research Institute of Pharmaceutical Science, Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
ABION Inc., R&D Center, 9th Fl., HanWha Biz Metro Bldg., 242 Digital-ro, Guro-gu, Seoul 152-733, Korea
Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Seoul 158-710, Korea
Author to whom correspondence should be addressed.
Academic Editors: Jacqueline Guidry, Stephen K. Tyring and Christopher Downing
J. Clin. Med. 2015, 4(5), 1126-1155;
Received: 27 January 2015 / Accepted: 8 May 2015 / Published: 21 May 2015
(This article belongs to the Special Issue Clinical Advances of Human Papillomaviruses)
Human papillomaviruses (HPVs) are small DNA viruses; some oncogenic ones can cause different types of cancer, in particular cervical cancer. HPV-associated carcinogenesis provides a classical model system for RNA interference (RNAi) based cancer therapies, because the viral oncogenes E6 and E7 that cause cervical cancer are expressed only in cancerous cells. Previous studies on the development of therapeutic RNAi facilitated the advancement of therapeutic siRNAs and demonstrated its versatility by siRNA-mediated depletion of single or multiple cellular/viral targets. Sequence-specific gene silencing using RNAi shows promise as a novel therapeutic approach for the treatment of a variety of diseases that currently lack effective treatments. However, siRNA-based targeting requires further validation of its efficacy in vitro and in vivo, for its potential off-target effects, and of the design of conventional therapies to be used in combination with siRNAs and their drug delivery vehicles. In this review we discuss what is currently known about HPV-associated carcinogenesis and the potential for combining siRNA with other treatment strategies for the development of future therapies. Finally, we present our assessment of the most promising path to the development of RNAi therapeutic strategies for clinical settings. View Full-Text
Keywords: HPV E6 and E7 oncogenes; siRNA pool; cervical cancer HPV E6 and E7 oncogenes; siRNA pool; cervical cancer
Show Figures

Figure 1

MDPI and ACS Style

Jung, H.S.; Rajasekaran, N.; Ju, W.; Shin, Y.K. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J. Clin. Med. 2015, 4, 1126-1155.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop